Nektar Therapeutics
NKTR
179 hedge funds and large institutions have $2.35B invested in Nektar Therapeutics in 2015 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 70 increasing their positions, 50 reducing their positions, and 20 closing their positions.
75% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 20
52% more capital invested
Capital invested by funds: $1.55B → $2.35B (+$799M)
40% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 50
8% more funds holding
Funds holding: 166 → 179 (+13)
7% more call options, than puts
Call options by funds: $5.89M | Put options by funds: $5.51M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BM
Bridger Management
New York
|
+$21.4M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$17.1M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$10.4M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$8.11M |
| 5 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$5.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$40.2M |
| 2 |
State Street
Boston,
Massachusetts
|
-$19.1M |
| 3 |
VOYA Investment Management
Atlanta,
Georgia
|
-$14M |
| 4 |
BJCM
Blue Jay Capital Management
Los Angeles,
California
|
-$12.1M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
-$10.8M |
NKTR Hedge Fund Activity: Q4 2015 in Review
179 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q4 2015, worth a combined $2.35B — up 52% from $1.55B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new NKTR positions and 20 closed out — a net gain of 15 holders — while 70 added to existing stakes and 50 trimmed.
The largest buyer was Bridger Management, opening a new position worth an estimated $21.4M. The largest seller was Millennium Management, cutting an estimated $40.2M.
- 179 institutional investors held Nektar Therapeutics (NKTR) as of Q4 2015, up from 166 in Q3 2015.
- Funds reported $2.35B of Nektar Therapeutics stock for Q4 2015, up 52% quarter-over-quarter.
- 35 funds opened new Nektar Therapeutics positions in Q4 2015 and 20 closed out, a net change of +15 holders.
- The largest Nektar Therapeutics buyer in Q4 2015 was Bridger Management, an estimated $21.4M added.
- The largest Nektar Therapeutics seller in Q4 2015 was Millennium Management, an estimated $40.2M sold.
Based on aggregated 13F filings for Q4 2015.